Australia: The Regulatory and Reimbursement Environment
This article is the third in a three-part series that aims to provide sponsors with information about Australia as a highly attractive option for drug research and development. Australia offers a mature infrastructure and experienced, capable local resources, especially important given global geopolitical uncertainties. Here, we examine the clinical trial start-up processes, regulatory pathway, market access, pricing system, and pricing control, with particular emphasis on cell and gene therapy with a case study to illustrate.
Interested in more? Check out part 1 and part 2.
Related Insights
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
Six top tips to prepare for the new EU Clinical Trial Regulation
Apr 13, 2021
Related Insights
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
Six top tips to prepare for the new EU Clinical Trial Regulation
Apr 13, 2021